grant
Unlocking mechanisms of resistance to targeted therapy in thyroid cancer
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY2025ATM ProteinATM Serine/Threonine Protein KinaseATM kinaseATM protein kinaseAtaxia Telangiectasia MutatedAtaxia Telangiectasia ProteinAtaxia-Telangiectasia-Mutated protein kinaseB-raf-1BRAFBRAF geneBrainBrain Nervous SystemCRISPRCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas systemCRISPR/Cas9 screenCancersCarcinoma CellCell SurvivalCell ViabilityClinical DataClustered Regularly Interspaced Short Palindromic RepeatsCoupledDNA AlterationDNA DamageDNA InjuryDNA Sequence AlterationDNA mutationDiseaseDisorderEncephalonExhibitsExtracellular Signal-Regulated Kinase GeneGenesGenetic AlterationGenetic ChangeGenetic DeterminismGenetic PredispositionGenetic Predisposition to DiseaseGenetic SusceptibilityGenetic defectGenetic mutationGenetic propensityGenome InstabilityGenomic InstabilityGoalsHumanIn VitroInherited PredispositionInherited SusceptibilityKnock-outKnockoutLibrariesLinkLung CarcinomaMAP Kinase GeneMAPKMalignant CellMalignant Epithelial CellMalignant NeoplasmsMalignant Thyroid Gland NeoplasmMalignant TumorMalignant Tumor of the ThyroidMalignant Tumor of the Thyroid GlandMalignant neoplasm of thyroidMediatingMetabolicMetabolic PathwayMitogen-Activated Protein Kinase GeneModern ManMutationOncogenicOutcomeOxidative PhosphorylationOxidative Phosphorylation PathwayPTK InhibitorsPathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsProtein Tyrosine Kinase InhibitorsRAFB1ReportingResistanceRoleSequence AlterationSiteTK InhibitorsTherapeuticThyroid CancerToxic effectToxicitiesTyrosine Kinase Inhibitoranaplastic thyroid canceranaplastic thyroid carcinomaataxia telangiectasia mutated proteinbonecancer cellcell killingclustered regularly interspaced short palindromic repeats screengenetic determinantgenetic etiologygenetic mechanism of diseasegenetic vulnerabilitygenetically predisposedgenome mutationgenome scalegenome-widegenomewidegenomic alterationimprovedin vivoindividualized cancer careindividualized oncologyinhibitorknockout genemalignancymutantneoplasm/cancernovelpathwaypatient oriented outcomespersonalized oncologyprecision cancer careprecision cancer medicineprecision oncologyresistance mechanismresistantresistant mechanismresponseresponse to therapyresponse to treatmentsocial rolesynthetic lethal interactionsynthetic lethalitytargeted agenttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapy responsetreatment responsetreatment responsivenesstumorv-raf Murine Sarcoma Viral Oncogene Homolog B1
Description preview
Our major goal is to identify new determinants of resistance to targeted therapy and more specifically to BRAF inhibitors in advanced and metastatic thyroid cancer. Our overall hypothesis is that BRAFV600E driven-ATC cells heavily rely on certain genes or key pathways to survive canonical treatments targeting oncogenic BRAF: We have performed a…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click